Brain+ A/S develops digital therapeutics for Alzheimer's and dementia. The company develops cognitive stimulation therapy (CST), a therapy that treats the main symptoms of dementia; Computerized Cognitive Training, a cognitive training method for patients with mild cognitive impairment; and Starry Night, memory test for early detection and monitoring of Alzheimer's. In addition, it develops an interface for clinicians to track and trace the patient's treatment progress. The company was incorporated in 2012 and is based in Copenhagen, Denmark. Brain+ A/S was formerly a subsidiary of Brain+ Holding ApS.

Brain+ A/S

Brain+ is focused on developing digital Cognitive Stimulation Therapy (CST) to support individuals affected by dementia, providing clinically validated treatments to improve patient outcomes.

Brain+

Brain+ | 3,181 followers on LinkedIn. Helping people affected by dementia, live better lives | We are on a mission to build the world&#39;s first scalable dementia care platform, helping people affected by dementia to live better lives. At the core, we are pioneers of digital Cognitive Stimulation Therapy (CST), the world-leading non-drug dementia treatment recommended for global implementation and endorsed by the National Institute for health and Care Excellence (NICE) in the UK and the World Alzheimer&#39;s Association.

I maximize biz success! Seasoned pro in global channel, alliance, & marketing strategies. Expert in hybrid tech & cross-cultural collaboration…

Dag Cummings

CEO & Co-founder @ Brain+ | Brain Health | Digital Health | Key Note Speaker | xBCG

Kim Baden-Kristensen

Business Developer with great passion for Mental Health, Digital transformation and Change Management

Brian Østergaard

I am not a scientist nor a doctor, I am a human concerned for OUR health, contributing via digital/ tech solutions

Anish Shindore

Really excited to share our online event with you all and hope you can join us 💫 "Unlocking the value of Cognitive Stimulation Therapy: a best kept secret" 📅: 21st of October 🕰️: 11-12 (GMT) 📍: Online, link below Join us to hear from key experts on how innovative digital solutions can play a crucial role in expanding access to CST and overcoming critical implementation barriers. We look forward to your participation in this important conversation that could shape the future of dementia care 🧠

My husband and I were both architects specialising in the education sector. Ian was diagnosed with Alzheimer’s Disease in 2017 and died in 2022 aged 82. We had moved to Dorset in 2007 on his retirement. Here he created, planted and maintained a wonderful 2 acre garden and a 2 acre wood as well as designing an extension to the house and for our son’s first two houses. We led a very busy and active social and cultural life, grew our own vegetables and soft fruit and had a small flock of chickens. I am convinced that his slow but inexorable and heartbreaking mental and physical decline was slowed down by us having led such a busy and active life both physically and mentally. We continued this for as long as possible after his diagnosis, including going on holiday to Vietnam, and on study tours in this country. By 2019 he no longer knew who I was or indeed that he had been married, but he still enjoyed my company and , until the restrictions of Covid, going out to lectures, visits and meals with friends. I strongly feel that our DIY (Do-It-Yourself) version of CST helped me as well as him. While each person and each carer’s experience of dementia is unique, I hope that I can bring to Brain+ my experience of caring for my husband, and of the organisations that helped us and the difficulties that we encountered. Liz in Brain+ Liz is our UK patient advocate helping us in many ways. Her firsthand experience of caring for a family member with dementia is an invaluable asset to developing our products. Thank you Liz 🙏🙌 Kim

An amazing event attended by our Chief Commercial Officer Devika Wood, MPH in the UK, the leading tech ecosystem globally 🚀

A few days ago, the Care Quality Commission released their annual report on 'the state of health care and adult social care in England 2023/24'. There is a huge imperative for CQC to use its role to improve the experience of using health and social care services for people living with dementia, and their carers. Read our article to find out how 🌟🧠 and let us know your thoughts and comments 👇🏼 To read the full report, the link is in the comments below!

Highlights from LSX Nordic Congress 2024! 🎤✨ A huge thank you to Nadia Moodie (Konneh) , Natasha Bank , the LSX team, and my fellow panel members— Kim Baden-Kristensen , Thomas Lethenborg , and Jeremy McCrohan . Our CEO Katarina Hedbeck says, ''it was a pleasure to be in the panel with you to discussion on the right time to start with commercialisation.'' We are grateful to everyone who attended and engaged with us in Copenhagen, making it a truly inspiring experience. The conversations and potential collaborations have left us excited about driving the future of healthcare forward! Looking forward to continued partnerships and impactful solutions ahead. 🌍💡 #LSXNordic #HealthcareInnovation #MedTech #Collaboration #Interlinked #ReLink #PatientSafety #LinkUS #TadaGroup #TadaMedical

Interlinked AB

This year we conducted our UK usability study at to AgeUK sites I am proud to say. Age UK is one of the largest UK charities for seniors a leading force in the sector, offering a wide range of services and advocacy for older people, and probably the largest provider of Cognitive Stimulation Therapy (CST) in the UK. We have a common purpose to change the way we age for the better. I look forward to work more with AgeUK and other like-minded UK institutions as we begin to make CST available at scale in the UK 🇬🇧💙 . Much love, Kim https://lnkd.in/dGt3ndWp

‼️Crucial insights on Alzheimer's Care 🧠 In a landscape where Alzheimer's treatments are rapidly evolving, the recent rejection of donanemab for widespread use by the NHS , coupled with the lack of approval for lecanemab, underscores a critical gap in effective therapeutic options. This moment highlights the urgent need to turn our attention to proven interventions like Cognitive Stimulation Therapy (CST). ❗️The Memory Assessment Service Audit 2023/24 reveals significant limitations in the current provision of CST, despite its endorsement by the National Institute for Health and Care Excellence (NICE) as essential for combating cognitive decline in dementia patients. 🧠 Research has shown that CST can delay cognitive decline by 4-6 months, making it a vital tool for enhancing the quality of life for individuals with dementia. 💕Pioneering studies, such as those by Spector et al. (2003) and Orrell et al. (2007), demonstrate that regular engagement in CST can lead to substantial improvements in cognitive function and overall well-being. Recent meta-analyses by Desai et al. (2024) and the Cochrane Review by Woods et al. (2023) further reinforce these findings, emphasizing CST's effectiveness in promoting sustained cognitive benefits. 🚀 At Brain+, we recognise the challenges in delivering CST at scale. Our CST Assistant is designed to facilitate provision through workforce optimisation, capacity release, and greater throughput, allowing more patients to benefit from this essential therapy. 🏆 By streamlining processes and enhancing resource allocation, we can ensure that those affected by Alzheimer’s receive the vital support they need now, while we work towards future innovations. Let’s champion effective care solutions that truly make a difference! 🌟 #CognitiveStimulationTherapy #AlzheimersCare #NHS #HealthcareInnovation #NICERecommendations #Lecanemab #BrainPlus

Congratulations to team Brain+ for being shortlisted as 1 of the 10 innovative companies shortlisted for the BioCap pitching competition that took place last month in Manchester as part of the Bionow conference ✨ Our Chief Commercial Officer, Devika Wood, MPH presented our 7 minute pitch to the judges, which can be watched here 🤩 Congratulations to the winner of the pitching competition Ocuwell 🏆

Amazing job team! Fiona Costello Devika Wood, MPH Nahid Zokaei 💕 and thank you to all the participants for an engaging conversation, including how CST is practically being delivered and changing lives! We can't wait to host the next webinar in our series, we will be sharing the date soon!

Brain+ is hosting Unlocking the value of Cognitive Stimulation Therapy: a best kept secret. Make sure to attend it today ☺️

	Jun '22	Dec '22	Jun '23	Jun '24
net income	-4.12M -	-5.56M 34.95%	-6.07M 9.25%	-7.06M 16.19%
depreciation and amortization	813.90K -	813.89K 0.00%	2.03M 149.93%	2.05M 0.61%
deferred income tax	-804.63K -	347.33K 143.17%
stock based compensation	-1.61M -	3.81M 337.18%
change in working capital	20.07K -	5.44M 27,008.86%		-381.96K -
accounts receivables	1.10M -	1.10M 0.45%		228.02K -
inventory
accounts payables	-1.08M -	4.34M 501.61%		-609.98K -
other working capital
other non cash items	1.03M -	-4.21M 509.06%	8.11M 292.47%	4.47M 44.86%
net cash provided by operating activities	-4.67M -	642.98K 113.77%	4.07M 532.74%	-5.40M 232.66%
investments in property plant and equipment	-2.80M -	-2.22M 20.54%		-2.05M -
acquisitions net
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites	-2.80M -	-2.22M 20.54%		-2.05M -
debt repayment	-7.92K -	-7.92K 0%		-1.56M -
common stock issued		5.46M -		7.47M -
common stock repurchased
dividends paid
other financing activites		-87 -
net cash used provided by financing activities	7.92K -	5.45M 68,745.23%		9.03M -
effect of forex changes on cash		2 -
net change in cash	-7.46M -	3.87M 151.87%	-1.11M 128.67%	1.58M 242.82%
cash at beginning of period	9.99M -	2.53M 74.65%	6.40M 152.76%	3.09M 51.72%
cash at end of period	2.53M -	6.40M 152.76%	5.29M 17.33%	4.68M 11.66%
operating cash flow	-4.67M -	642.98K 113.77%	4.07M 532.74%	-5.40M 232.66%
capital expenditure	-2.80M -	-2.22M 20.54%		-2.05M -
free cash flow	-7.47M -	-1.58M 78.82%	4.07M 357.26%	-7.45M 283.12%

BRAI

COM:BRAIN-PLUS

Brain+

Last Close

0.09

22/11 15:15

Market Cap

20.96M

Beta: -

Volume Today

99.51K

Avg: -

Preview